About involuntary movements

Select condition:

All patients taking antipsychotic drugs (APDs) are at risk for developing tardive dyskinesia (TD)1

The number of people affected by tardive dyskinesia in the US.
  • OVER 7 MILLION PEOPLE in the US are taking APDs that can lead to TD2
  • The number of people affected by tardive dyskinesia in the US is approximately 500,000 AND GROWING. Approximately 65,000 have been diagnosed2,3
The amount of people living with tardive dyskinesia that are undiagnosed.
  • <15% OF PATIENTS are formally diagnosed2,3
  • Most people living with tardive dyskinesia ARE UNDIAGNOSED2,3

TD is a variable condition that goes beyond physical movements

Tardive dyskinesia can vary from patient to patient and the impact may not always correlate with the severity of symptoms4-6

  • TD affects different parts of the body in different patients
  • Tardive dyskinesia symptoms can wax and wane
  • Involuntary movements may be subtle or obvious

Regardless of severity, tardive dyskinesia impacts patients in more ways than just involuntary movement*

Brain representing psychiatric stability.

Psychiatric stability7,8

  • Poor response to treatment
  • Risk of relapse/readmission
Two people talking representing psychosocial state.

Psychosocial state4,6,7

  • Social isolation
  • Fewer leisure activities
  • Feelings of embarrassment or self-consciousness
Two gears representing the ability to function.

Ability to function7,9

  • Personal grooming difficulties
  • Impaired ability to work
Person representing physical health.

Physical health4,5

  • Pain
  • Dental and gait issues

*There are no data to suggest that AUSTEDO (deutetrabenazine) tablets affect any of these outcomes.

Lessening the impact of TD symptoms is an important goal, regardless of the severity of dyskinesia.6
Learn more about why AUSTEDO may be right for the diverse treatment needs of your patients.
REGISTER FOR UPDATES

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176. doi:10.1007/s13311-013-0222-5 2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 3. Dhir A, Schilling T, Abler V, Potluri R, Carroll B. Estimation of tardive dyskinesia incidence and prevalence in the United States. In: Proceedings from the International Congress of Parkinson’s Disease and Movement Disorders; Vancouver, Canada; June 4-8, 2017. Abstract 411. 4. Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention. Nova Science Publishers, Inc; 2013:235-258. 5. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1. Published online July 12, 2013. doi:10.7916/D88P5Z71 6. Sharing the impact of tardive dyskinesia. National Alliance on Mental Illness website. Accessed April 17, 2020. https://notalone.nami.org/post/97568253959/sharing-the-impact-of-tardive-dyskinesia] 7. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580-8. 8. Caroff SN, Campbell EC, Carroll B.Pharmacological treatment of tardive dyskinesia: recent developments. Expert Rev Neurother. 2017(9):871-881. Published July 31, 2017. doi:10.1080/14737175.2017.1358616 9. Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M; Tardive Dyskinesia Assessment Working Group. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79(3). pii: 17cs11959. doi:10.4088/JCP.17cs11959